OleanderUSFDA approves Phoenix IND 73,624 application to conduct a Phase I Trial with PBI-05204, a patented supercritical extract of Nerium oleander, in patients with advanced cancer. Posted on August 2007June 2022 by Carlos Torres 06 Aug Phoenix enters into contract with Quintiles, Inc. to act as Clinical Research Organization for “An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients” to be conducted at M. D. Anderson Cancer Center. Phoenix executes an amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center
